Guardant Health
Guardant Health: A Palo Alto-based biotech firm providing global cancer diagnostics and sequencing services.
Founded
2011Guardant Health: A Palo Alto-based biotech firm providing global cancer diagnostics and sequencing services.
Official pages and third-party coverage in one index.
guardanthealth.com31 items across 19 mapped pages · Crawled Sep 24, 2026
Official pages and third-party coverage in one index
Test your advanced breast cancer patients for ESR1 mutations before disease progression at no added cost.*
Guardant Reveal™ is a tissue-free blood test that monitors ctDNA across the care continuum - from MRD detection to therapy response monitoring
Guardant360® Liquid CDx is the largest FDA-approved liquid biopsy, delivering genomic and epigenomic insights for comprehensive cancer profiling. Learn more.
Guardant360® Tissue is the most advanced multiomic tissue biopsy that delivers DNA, RNA, and epigenomic insights. Medicare-covered for all advanced solid tumors.
Find important resources from Guardant, including insurance and medicare coverage, the myGuardant patient portal, and at-home blood draw services near you.
Stay updated with the latest news and stories on Guardant Health. Explore more for comprehensive coverage and news insights.
Access the most up-to-date resources and multimedia assets related to our company and products.
Explore Guardant Health newsroom for the latest press releases and news coverage. Contact our global communications team for more information.
Explore the latest press releases from Guardant Health. Stay informed about our groundbreaking advancements in healthcare biotechnology.
Guardant's leadership team is composed of proven executives passionate about transforming cancer care for patients.
Advocating for access to modern cancer screenings. There have been more than 9.5 million missed cancer screenings in the United States as a result of the COVID-19 pandemic.1 Advancements in innovative cancer screening technologies have the potential to get Americans back on track with recommended screenings and save lives.
Outdated guidelines are keeping millions of eligible Americans from life-saving blood-based screening options. It’s time for action.
Our mission is to conquer cancer with data. It's an ambitious pursuit that requires a singular focus and a relentless commitment to patients.
Our support teams are committed to providing the best support possible. Contact us if you have questions, need assistance, or like to access our Whistleblower Hotline.
Guardant Health is a leading precision medicine company focused on transforming patient care and conquering cancer with data.
Enhance your experience with Guardant Health through our use of cookies and tracking technologies. Read our Cookie Policy to understand how we utilize these tools.
This policy describes the types of data we collect on our careers sites, how we may use that data and the rights you may have regarding our use of your personal data.
Discover the terms and conditions of use for Guardant Health's data transfer services and terms of use.
Access Guardant Health's detailed website terms of use and data transfer terms and conditions. Stay up-to-date on our data policies.
Explore Guardant Health's website terms of use and data transfer terms and conditions. Learn more about our policies and guidelines.
Guardant Health is a leading precision medicine company focused on transforming patient care and conquering cancer with data.
Empirik, a Sequoia-incubated infrastructure startup, spins out independently with $21 million in seed funding from Sequoia, Canapi, and Alumni Ventures to predict outages by tracking system changes and their potential effects across infrastructure. Led by CEO Kartik Chandrayana, it permits low-risk changes, sets guardrails on larger updates, and flags dangerous ones for human review. Its customers include Guardant Health and a major consumer packaged goods company.
Sep 2026 · TechCrunchNews article
A federal judge orders Guardant Health to pay more than $245 million to TwinStrand Biosciences and the University of Washington over infringement of patents covering Duplex Sequencing. The judgment includes $83.4 million in jury damages, $19.5 million in supplemental damages, $119.4 million in accrued royalties and $22.9 million in interest, and requires a 6% royalty on covered sales through March 2033. Guardant says collection will be stayed pending appeal and plans to challenge the ruling.
Aug 2026 · GeekWireNews article
GitHubRepository owner